통증 관리 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Pain Management Therapeutics Market size is expected to reach USD 130.21 Billion in 2034 from USD 89.76 Billion (2025) growing at a CAGR of 4.22% during 2026-2034.

The pain management therapeutics market is set to experience substantial growth as the global burden of chronic pain continues to escalate. With an increasing number of individuals suffering from conditions such as arthritis, neuropathy, and fibromyalgia, the demand for effective pain relief solutions is paramount. The market is witnessing a shift towards more holistic and patient-centered approaches, with a growing emphasis on non-opioid alternatives and multimodal therapies. This trend is driven by the rising awareness of the risks associated with opioid use, prompting healthcare providers to explore innovative treatments that address pain without the potential for addiction.

Advancements in biotechnology and pharmacology are paving the way for the development of novel pain management therapeutics. Biologics, including monoclonal antibodies and gene therapies, are emerging as promising options for targeting specific pain pathways, offering the potential for more effective and personalized treatment regimens. Additionally, the integration of digital health technologies, such as wearable devices and mobile applications, is revolutionizing pain management by enabling real-time monitoring and data collection. These innovations not only empower patients to take an active role in their pain management but also provide healthcare professionals with valuable insights to tailor treatment plans more effectively.

The future of the pain management therapeutics market will also be influenced by regulatory changes and reimbursement policies that prioritize patient access to innovative therapies. As clinical evidence supporting the efficacy of non-opioid treatments continues to grow, regulatory bodies are likely to expedite the approval processes for these alternatives, fostering a more competitive landscape. Furthermore, the establishment of reimbursement frameworks that recognize the value of comprehensive pain management strategies will encourage healthcare providers to adopt these innovative solutions. As the market matures, the focus will shift towards integrating pain management into broader healthcare strategies, emphasizing the importance of addressing both physical and psychological aspects of pain. This holistic approach will not only enhance patient outcomes but also contribute to the overall efficiency of healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Pain Type

• Chronic
• Acute

By Drug Class

• NSAIDS
• Anesthetics
• Anticonvulsant
• Anti-migraine Drugs,
• Antidepressant Drugs
• Opioids
• Non-narcotics
• Analgesics

By Indication

• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Pain
• Post-operative Pain
• Migraine
• Fibromyalgia
• Bone Fracture
• Muscle
• Sprain/Strain
• Acute Appendicitis
• Others

COMPANIES PROFILED

• Johnson Johnson, Novartis International AG, Merck Co, Inc, GlaxoSmithKline plc, Pfizer Inc, Abbott Laboratories, Teva Pharmaceuticals, Eli Lilly and Company, Endo Health Solutions, Inc, Allergan, Inc, Covidien plc, Durect Corporation, Hospira, Inc, Mundipharma International Ltd, Forest Laboratories, Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET: BY PAIN TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Pain Type
• 4.2. Chronic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Acute Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. NSAIDS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Anesthetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Anticonvulsant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Anti-migraine Drugs, Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Antidepressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Opioids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Non-narcotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Analgesics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Arthritic Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Neuropathic Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Chronic Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Post-operative Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Migraine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Fibromyalgia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Bone Fracture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Muscle Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.11. Sprain/Strain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.12. Acute Appendicitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.13. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Pain Type
  • 7.2.2 By Drug Class
  • 7.2.3 By Indication
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Pain Type
  • 7.3.2 By Drug Class
  • 7.3.3 By Indication
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Pain Type
  • 7.4.2 By Drug Class
  • 7.4.3 By Indication
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Pain Type
  • 7.5.2 By Drug Class
  • 7.5.3 By Indication
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Pain Type
  • 7.6.2 By Drug Class
  • 7.6.3 By Indication
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PAIN MANAGEMENT THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Johnson & Johnson
  • 9.2.2 Novartis International AG
  • 9.2.3 Merck & Co.Inc
  • 9.2.4 GlaxoSmithKline Plc
  • 9.2.5 Pfizer Inc
  • 9.2.6 Abbott Laboratories
  • 9.2.7 Teva Pharmaceuticals
  • 9.2.8 Eli Lilly And Company
  • 9.2.9 Endo Health SolutionsInc
  • 9.2.10 AllerganInc
  • 9.2.11 Covidien Plc
  • 9.2.12 Durect Corporation
  • 9.2.13 HospiraInc
  • 9.2.14 Mundipharma International Ltd
  • 9.2.15 Forest LaboratoriesInc